Form 4: Revolution Medicines General Counsel Sells Shares Under 10b5-1 Plan

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,554 shares of common stock at an average price of $55.1337, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, sold 2,554 shares of common stock on November 15, 2024.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on March 20, 2024.
• The shares were sold at a weighted average price of $55.1337, with individual trades ranging from $54.91 to $55.51.
• Following the transaction, Cislini still beneficially owns 43,080 shares, which includes 40,209 restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates that the sale was pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• Similar filings are regularly made by executives at companies like Amgen, Gilead, and Regeneron, reflecting routine stock transactions under pre-arranged plans.
• The reported sale is relatively small compared to the overall market capitalization of Revolution Medicines and is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on investor sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, insider trading, 10b5-1 plan, stock sale, Revolution Medicines, RVMD, Jeff Cislini, General Counsel